[ CAS No. 259808-67-8 ] {[proInfo.proName]}

Name: 259808-67-8|tert-Butyl 3,3-dimethylpiperazine-1-carboxylate|98%
Brand: Ambeed
SKU: A144839
Price: 10.0 USD
Availability: InStock
Rating: 97 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 259808-67-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 259808-67-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 259808-67-8 ]

SDS Specification

Alternatived Products of [ 259808-67-8 ]

Product Details of [ 259808-67-8 ]

CAS No. :	259808-67-8	MDL No. :	MFCD07371651
Formula :	C₁₁H₂₂N₂O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	LBAIYWWWORXVEQ-UHFFFAOYSA-N
M.W :	214.30	Pubchem ID :	22710387
Synonyms :

Calculated chemistry of [ 259808-67-8 ]

Physicochemical Properties

Num. heavy atoms :	15
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.91
Num. rotatable bonds :	3
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	68.15
TPSA :	41.57 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.85 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.95
Log Po/w (XLOGP3) :	1.07
Log Po/w (WLOGP) :	0.84
Log Po/w (MLOGP) :	1.15
Log Po/w (SILICOS-IT) :	1.08
Consensus Log Po/w :	1.42

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.64
Solubility :	4.86 mg/ml ; 0.0227 mol/l
Class :	Very soluble
Log S (Ali) :	-1.53
Solubility :	6.26 mg/ml ; 0.0292 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.05
Solubility :	1.92 mg/ml ; 0.00897 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.37

Safety of [ 259808-67-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 259808-67-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 259808-67-8 ]
Downstream synthetic route of [ 259808-67-8 ]

[ 259808-67-8 ] Synthesis Path-Upstream 1~3

1
[ 24424-99-5 ]
[ 84477-72-5 ]
[ 259808-67-8 ]

Yield	Reaction Conditions	Operation in experiment
96%	at 0 - 20℃; for 4 h;	To a solution of 2,2-dimethylpiperazine (400 mg) in dichloromethane (20 mL) at 0° C. was added di-tert-butyl dicarbonate (766 mg). The reaction was stirred at room temperature for 4 h and then quenched with water (20 mL) and extracted into dichloromethane (2*40 mL). The combined organics were washed with saturated aqueous brine solution (40 mL), dried (MgSO₄) and concentrated to give 3,3-diemethyl-piperazine-1-carboxylic acid tert-butyl ester as a white solid (720 mg, 96percent).

Reference： [1] Patent: US2008/76758, 2008, A1, . Location in patent: Page/Page column 90
[2] Patent: EP1104754, 2001, A1,
[3] Patent: WO2014/96151, 2014, A2, . Location in patent: Page/Page column 43
[4] Patent: WO2018/218197, 2018, A2, . Location in patent: Paragraph 0369

2
[ 24424-99-5 ]
[ 259808-67-8 ]

Yield	Reaction Conditions	Operation in experiment
69%	With triethylamine In tetrahydrofuran at 20℃; Cooling with ice	Compound (I'-161): To a mixture of 6.02 g (0.01760 mole) of 2,2-dimethylpiperazine-2 trifluoroacetate, 7.8 ml (0.0563 mole) of triethylamine and 30 ml of tetrahydrofuran was added dropwise 4.2 ml (0.01848 mole) of di-tsrt-butyl dicarbonate under ice-cooling, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and 1N-aqueous HCl and diisopropyl ether were added, and extracted. The aqueous layer was alkalified with 2N-aqueous NaOH, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate, and the solvent was concentrated under reduced pressure to give 2.6 g (69percent) of 1-tert-butoxycarbonyl 3,3-dimethylpiperazine as a pale yellow liquid. 1H-NMR(CDCl3): δ(ppm) 1.11 (6H, s), 1.46 (9H, s), 2.87 (2H, t, J=5Hz), 3.16 (2H, s), 3.36 (2H, t, J=5Hz).

Reference： [1] Patent: EP2208728, 2010, A1, . Location in patent: Page/Page column 142

3
[ 58632-95-4 ]
[ 84477-72-5 ]
[ 259808-67-8 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 24, p. 6017 - 6021

[ 259808-67-8 ] Synthesis Path-Downstream 1~88

1
[ 124-63-0 ]
[ 259808-67-8 ]
[ 956034-41-6 ]

Yield	Reaction Conditions	Operation in experiment
93%	With triethylamine; In dichloromethane; at 0 - 20℃; for 16h;	To a solution of 3,3-diemethyl-piperazine-1-carboxylic acid tert-butyl ester (720 mg) and triethylamine (0.59 mL) in dichloromethane (10 mL) at 0 C. was added dropwise methanesulfonyl chloride (0.30 mL). The reaction mixture was stirred at room temperature for 16 h and then quenched with water (10 mL) and extracted into dichloromethane (220 mL). The combined organic layers were washed with saturated aqueous brine solution (220 mL), dried (MgSO4) and concentrated to give 4-methanesulfonyl-<strong>[259808-67-8]3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> as a white solid (914 mg, 93%).
88%	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	To a solution of tert-butyl 3,3-dimethylpiperazine-l-carboxylate (500 mg, 2.333 mmol) in DCM (11 ml) at 0 C was added TEA (0.976 ml, 7.00 mmol) and methanesulfonyl chloride (321 mg, 2.80 mmol) and the resulting mixture was stirred RT for 3 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (5 - 100 % EtOAc in hexanes) to give tert-butyl 3,3-dimethyl-4-(methylsulfonyl)piperazine-l-carboxylate (600 mg, 2.052 mmol, 88 % yield) as a colorless liquid. MS (ES+) C^H^C^S requires: 292, found: 293 [M+H] +.
	With triethylamine; In dichloromethane; at 0 - 20℃; for 2h;	To a solution of 27 (1.00 g, 4.6 mmol) in CH2C12 (10 mL) at0C was charged with Et3N (2.30 g, 23 mmol) followed by MsC1 (0.59 mg, 7.0 mmol). The reaction mixture was stirred at room temperature for 2 h. Water (50 mL) was added to the reaction mixture and extracted with CH2C12 (2 x 50 mL). The organic phase was separated, dried over anhydrous Na2504, filtered and concentrated to afford 28 [1.20 g (cmde)j as a solid, whichwas used for the next step without further purification.

	With triethylamine; In dichloromethane; at 0 - 20℃; for 3h;	To a solution of the product from the previous step (1.0 g, 4.7 mmol) in CH2Cl2 (20 mL) at 0 C were added TEA (2.0 ml, 14 mmol) and methanesulfonyl chloride (0.641 g, 5.60 mmol) and the resulting mixture was stirred RT for 3 h. The mixture was concentrated under reduced pressure. The residue was purified via silica gel chromatography (5 - 100 % EtOAc in hexanes) to afford a colorless liquid. The residue was taken up in CH2CI2 (20 mL), 4 N HCl in dioxane (3.5 mL, 14 mmol) was added and the mixture was stirred at RT for 14 h. A white ppt was collected by vacuum filtration to afford the title compound (716 mg, 80 % yield).
270 mg	With potassium carbonate; In dichloromethane; at 20℃; for 4h;	To a stirring solution of <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (300 mg, 1.4 mmol) in DCM (3 mL) was added MsCl (321 mg, 2.8 mmol) and K2CO3(425 mg, 4.2 mmol). After being stirred at 20 C for 4 hrs, the resulting mixture was diluted with DCM (80 mL), then washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2S04and concentrated in vacuo. The residue was purified by column chromatography (eluting with PE/EA=5/1, v:v) to give tert-butyl 3,3-dimethyl-4-methylsulfonyl-piperazine-l-carboxylate (270 mg) as a colorless oil.

Reference： [1]Patent: US2008/76758,2008,A1 .Location in patent: Page/Page column 90
[2]Patent: WO2018/136887,2018,A1 .Location in patent: Page/Page column 121
[3]Patent: WO2017/7700,2017,A1 .Location in patent: Page/Page column 122
[4]Patent: WO2018/218197,2018,A2 .Location in patent: Paragraph 0369; 0370
[5]Patent: WO2018/1952,2018,A1 .Location in patent: Page/Page column 120; 121

2
[ 259808-67-8 ]
[ 852444-43-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 6017 - 6021

3
[ 259808-67-8 ]
(R)-1-{2,2-Dimethyl-4-[5-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-3-(2-methyl-benzothiazol-5-yloxy)-propan-2-ol [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 6017 - 6021

4
[ 102153-63-9 ]
[ 259808-67-8 ]
4-(tert-butoxycarbonyl)-1-[(6-chloronaphthalen-2-yl)sulfonyl]-2,2-dimethylpiperazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium chloride; triethylamine; In dichloromethane;	[Referential Example 281] 4-(tert-Butoxycarbonyl)-1-[(6-chloronaphthalen-2-yl)sulfonyl]-2,2-dimethylpiperazine To a solution of 1-(tert-butoxycarbonyl)-3,3-dimethylpiperazine (125 mg) in methylene chloride (3.0 ml) were added triethylamine (90 ml) and 6-chloronaphthalene-2-sulfonyl chloride (167 mg). The resulting mixture was stirred at room temperature for 84 hours. The reaction mixture was diluted with methylene chloride and added with a saturated aqueous solution of sodium chloride to form two layers. The organic layer obtained by separation was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crudely purified product was purified by chromatography on a silica gel column (hexane: ethyl acetate = 8:1), whereby the title compound (155 mg) was obtained as a colorless solid. 1H-NMR (CDCl3) delta: 1.31(6H,s), 1.44(9H,s), 3.22(2H,br s), 3.49-3.62(2H,br), 3.57-3.62(2H,br), 7.56(1H,dd,J=8.8,2.0Hz), 7.79(1H,d,J=8.8Hz), 7.86(1H,s), 7.87-7.92(3H,m), 8.36(1H,s).

Reference： [1]Patent: EP1104754,2001,A1

5
[ 4385-76-6 ]
[ 259808-67-8 ]
4-(tert-Butoxycarbonyl)-2,2-dimethyl-1-[4-(pyridin-4-yl)benzoyl]piperazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium chloride; sodium hydrogencarbonate; triethylamine; In N,N-dimethyl-formamide;	[Referential Example 283] 4-(tert-Butoxycarbonyl)-2,2-dimethyl-1-[4-(pyridin-4-yl)benzoyl]piperazine To a solution of 1-(tert-butoxycarbonyl)-3,3-dimethylpiperazine (173 mg) in a mixture of N,N-dimethylformamide (2.5 ml) and triethylamine (1.0 ml) was added (4-nirophenyl) 4-(4-pyridyl)benzoate (330 mg). The resulting mixture was stirred at 60°C for 5 days. The reaction mixture was diluted with methylene chloride and then added with a saturated aqueous solution of sodium chloride to form two layers. The organic layer obtained by separation was washed with a saturated aqueous solution of sodium bicarbonate and an aqueous solution of sodium chloride, dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The crudely purified product was purified by chromatography on a silica gel column (methylene chloride: methanol = 50:1), whereby the title compound (199 mg) was obtained as colorless amorphous. 1H-NMR (CDCl3) delta: 1.49(9H,s), 1.61(6H,s), 3.45-3.56(6H,m), 7.50(2H,d,J=5.9Hz), 7.51(2H,d,J=7.8Hz), 7.67(2H,d,J=7.8Hz), 8.69(1H,d,J=5.9Hz). MS (FAB) m/z: 369 (M+H)+.

Reference： [1]Patent: EP1104754,2001,A1

6
[ 24424-99-5 ]
[ 84477-72-5 ]
[ 259808-67-8 ]

Yield	Reaction Conditions	Operation in experiment
96%	In dichloromethane; at 0 - 20℃; for 4h;	To a solution of 2,2-dimethylpiperazine (400 mg) in dichloromethane (20 mL) at 0 C. was added di-tert-butyl dicarbonate (766 mg). The reaction was stirred at room temperature for 4 h and then quenched with water (20 mL) and extracted into dichloromethane (2*40 mL). The combined organics were washed with saturated aqueous brine solution (40 mL), dried (MgSO4) and concentrated to give 3,3-diemethyl-piperazine-1-carboxylic acid tert-butyl ester as a white solid (720 mg, 96%).
	In dichloromethane;	[Referential Example 280] 1-(tert-Butoxycarbonyl)-3,3-dimethylpiperazine To a methylene chloride solution (5.0 ml) of 2,2-dimethylpiperazine (460 mg, 4.03 mmol) (J. Med. Chem., 1995, 38, 4389) was added di-tert-butyl dicarbonate (780 mul). The resulting mixture was stirred for 3 hours. The reaction mixture was diluted with methylene chloride and then added with saturated aqueous NaCl solution to separate into two layers. The water layer thus obtained was extracted with methylene chloride. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crudely purified product was purified by chromatography on a silica gel column (methylene chloride: methanol = 10:1), whereby the title compound (360 mg) was obtained as a colorless oil. 1H-NMR (CDCl3) delta: 1.19(6H,s), 1.46(9H,s), 2.93(2H,t,J=4.9Hz), 3.23(2H,s), 3.42-3.48(2H,br), 3.95-4.01(1H,s).
	In ethanol; at 9 - 15℃; for 2.5h;Inert atmosphere;	2,2-dimethylpiperazine (1 1 .5 kg, 101 mol) was dissolved in ethanol (48.5 L) and the solution was cooled to approximately 9C. Di-tert-butyl dicarbonate (21 .9 kg, 100 mol) was dissolved in ethanol (41 .7 L). The solution of di-tertbutyl dicarbonate was added to the solution of dimethylpiperazine over a period of 2 h 30 min, keeping the temperature of the reaction below 15C. Ethanol (12.4 L) was added and the solution was stirred overnight at a temperature between 12-25C. The reaction was warmed to reflux and 75 L were distilled off. Ethanol (76 L) was added to the reaction and the solution was heated to 52C and transferred to a suspension of D,L-tartaric acid (7.5 kg, 50.0 mol) in ethanol (25.2 L), and warmed to 51 C. Ethanol (25.3 L ) was added and the reaction was kept at 20C overnight. The precipitate was filtered off and washed with ethanol (28.1 L). The solid was dried in a vacuum oven at 50C overnight to yield compound (XVIII) (27.1 kg, 93%) with 99% purity according to GC analysis.

In dichloromethane; at 0 - 20℃; for 14h;

To a solution of 2,2-dimethylpiperazine (1.50 g, 13.1 mmol) in CH2Cl2 (119 mL) at 0 C was added BOC2O (2.8 mL, 12 mmol) and the resulting mixture was stirred at RT for 14 h. The mixture was concentrated under reduced pressure and taken on to the next step without purification

Reference： [1]Patent: US2008/76758,2008,A1 .Location in patent: Page/Page column 90
[2]Patent: EP1104754,2001,A1
[3]Patent: WO2014/96151,2014,A2 .Location in patent: Page/Page column 43
[4]Patent: WO2018/218197,2018,A2 .Location in patent: Paragraph 0369

7
[ 683-57-8 ]
[ 259808-67-8 ]
[ 1148003-51-3 ]

Yield	Reaction Conditions	Operation in experiment
	With tetra-(n-butyl)ammonium iodide; potassium carbonate; In acetonitrile; at 60℃; for 18h;	Reference Example 46 2-(2,2-Dimethyl-piperazin-l-yl)-acetamideTo a solution of 3,3-dimethyl-piperazine-l-carboxylic acid tert-butyl ester (0.55 g, 2.57 mmol) in acetonitrile (10 mL) were added 2-bromoacetamide (0.42 g, 3.08 mmol), potassium carbonate (1.06 g, 7.70 mmol) and tetrabutylammonium iodide (95 mg, 0.257 mmol). The reaction mixture was heated at 60 C for 18 h, then concentrated in vacuo. The resulting residue was partitioned between DCM and water. The organic layer was separated, dried (Na2SO4), and concentrated in vacuo to give 4-carbamoylmethyl-3,3-dimethyl- piperazine-1-carboxylic acid tert-butyl ester as a cream solid. 4-Carbamoylmethyl-3,3- dimethyl-piperazine-1-carboxylic acid tert-butyl ester was subsequently BOC-deprotected by using the general method to give the title compound as a white solid (0.43 g, 97 %). [M + H]+ 172.1

Reference： [1]Patent: WO2009/53716,2009,A1 .Location in patent: Page/Page column 79

8
[ 24424-99-5 ]
2,2-dimethylpiperazine ditrifluoroacetate [ No CAS ]
[ 259808-67-8 ]

Yield	Reaction Conditions	Operation in experiment
69%	With triethylamine; In tetrahydrofuran; at 20℃;Cooling with ice;	Compound (I'-161): To a mixture of 6.02 g (0.01760 mole) of 2,2-dimethylpiperazine-2 trifluoroacetate, 7.8 ml (0.0563 mole) of triethylamine and 30 ml of tetrahydrofuran was added dropwise 4.2 ml (0.01848 mole) of di-tsrt-butyl dicarbonate under ice-cooling, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and 1N-aqueous HCl and diisopropyl ether were added, and extracted. The aqueous layer was alkalified with 2N-aqueous NaOH, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate, and the solvent was concentrated under reduced pressure to give 2.6 g (69%) of 1-tert-butoxycarbonyl 3,3-dimethylpiperazine as a pale yellow liquid. 1H-NMR(CDCl3): delta(ppm) 1.11 (6H, s), 1.46 (9H, s), 2.87 (2H, t, J=5Hz), 3.16 (2H, s), 3.36 (2H, t, J=5Hz).

Reference： [1]Patent: EP2208728,2010,A1 .Location in patent: Page/Page column 142

9
[ 1191-95-3 ]
[ 259808-67-8 ]
[ 1240914-33-3 ]

Yield	Reaction Conditions	Operation in experiment
		Tert-butyl 3,3-dimethylpiperazine-1-carboxylate (413 mg, 1.65 mmol) was dissolved in DCE (15 mL). TEA (1.148 mL, 8.23 mmol) was added, followed by cyclobutanone (231 mg, 3.29 mmol) and sodium triacetoxyborohydride (524 mg, 2.47 mmol). The reaction mixture was stirred for 5 h and a few drops of acetic acid were added. The reaction mixture was heated at 40 C. for 4 days, cooled to rt, washed with sat NaHCO3, dried over MgSO4, filtered and concentrated under reduced pressure to give a dark yellow oil. The crude title compound was used in the next step without further purification.

Reference： [1]Patent: US2010/216812,2010,A1 .Location in patent: Page/Page column 44

10
trans-2-(4-carbamoylphenyl)cyclopropanecarboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-(trans-2-(4-carbamoylphenyl)cyclopropanecarbonyl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
52.6%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃;	Intermediate 14 was dissolved in DMF (20 mL). DIPEA (1.021 mL, 5.85 mmol) was added, followed by HOBT (395 mg, 2.92 mmol), EDC (561 mg, 2.92 mmol) and <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (587 mg, 2.34 mmol). The reaction mixture was stirred at rt overnight, concentrated under reduced pressure, redissolved in DCM, washed with 1M HCl and sat NaHCO3, dried over MgSO4, filtered and concentrated under reduced pressure. The crude material was purified on preparative HPLC UV using the long high pH shallow gradient method (Mobile phase: 30-50% B; A: H2O with 10 mM NH4CO3 and 0.375% NH4OH v/v, B: CH3CN, 30 min run) on XBridge Prep C18 OBD, 50×250 mm, 10 mum, Waters reverse phase column, giving 412 mg title compound (52.6%) as a solid. 1H NMR (400 MHz, CDCl3) delta ppm 1.22-1.35 (m, 1H) 1.38-1.55 (m, 9H) 1.71 (br. s., 1H) 1.94 (br. s., 1H) 2.47 (br. s., 1H) 2.88 (s, 3H) 2.96 (s, 3H) 3.32-3.59 (m, 4H) 3.65-3.85 (m, 2H) 5.77 (br. s., 1H) 6.16 (br. s., 1H) 7.17 (d, J=8.20 Hz, 2H) 7.75 (d, J=8.20 Hz, 2H); MS m/z 402.21 [M+H]+ (ESI).

Reference： [1]Patent: US2010/216812,2010,A1 .Location in patent: Page/Page column 49

11
[ 98-88-4 ]
[ 259808-67-8 ]
[ 1244740-86-0 ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine; In tetrahydrofuran;	To a solution of 1 ,1-dimethylethyl 3,3-dimethyl-1-piperazinecarboxylate (100mg, 0.467mol) in tetrahydrofuran (1 OmL) was added triethylamine (0.098ml_, 0.700 mmol) followed by dropwise addition of benzoyl chloride (0.06OmL, 0.513mmol). The reaction mixture was allowed to stir for 30 minutes. The reaction mixture was diluted with DCM (1OmL) and the solution was washed with saturated sodium bicarbonate solution (1OmL, twice), then (0.1 M, aq) HCI (1OmL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to yield 1 ,1-dimethylethyl 3,3-dimethyl-4- (phenylcarbonyl)-i-piperazinecarboxylate as a colourless oil (162mg, 100%), MS ES+ve m/z 319 (M+H)To 1 , 1 -dimethylethyl 3,3-dimethyl-4-(phenylcarbonyl)-1 -piperazinecarboxylate (162mg, 0.509 mmol) was added 1 M hydrochloric acid in 1 ,4 dioxane (1 OmL), followed by the addition of 3 drops of water. The reaction mixture was allowed to stir for 62hours. The reaction mixture was reduced in vacuo to yield colourless oil. The colourless oil was dissolved in methanol (1 OmL) and passed down a SCX-2 column washing with two column volumes methanol and eluting the product with three column volumes of 2N ammonia solution in methanol The fraction containing eluted product was reduced in vacuo to yield 2,2-dimethyl-1-(phenylcarbonyl)piperazine as a white solid (81 mg, 63%), MS ES+ve m/z 219 (M+H). To a solution of 2,2-dimethyl-1-(phenylcarbonyl)piperazine (81 mg, 0.318 mmol) in DCM (5m L) was added DIPEA (0.172mL, 0.986 mmol), followed by gradual addition of 4-cyanobenzenesulfonyl chloride (70.5mg, 0.350 mmol). The reaction mixture was allowed to stir for 1 hour.The reaction mixture was diluted with DCM (1 OmL) and the solution was washed with saturated sodium bicarbonate solution (1 OmL, twice), then with distilled water (1OmL). The organic layer was dried (MgSO4), filtered and reduced in vacuo to yield a transparent oil (160mg).The oil was then dissolved in 1 :1 MeCN/DMSO (0.9ml) and purified using MDAP (over 3 batches). The fractions containing product were combined and reduced in vacuo to yield the title compound as a white solid (48mg, 32%)1H-NMR (CDCI3) 51.58 (6H, s), 3.00 (2H, s), 3.15 (2H, t, J=5.6Hz), 3.47 (2H, t, J=5.6Hz), 7.31-7.48 (5H, m), 7.84-7.93 (4H, m).MS ES+ve m/z 384 (M+H).

Reference： [1]Patent: WO2010/102663,2010,A1 .Location in patent: Page/Page column 75-76

12
[ 32779-36-5 ]
[ 259808-67-8 ]
[ 1272973-74-6 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

13
[ 259808-67-8 ]
C₂₁H₃₅BN₄O₄ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

14
[ 259808-67-8 ]
[ 1272972-75-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

15
[ 259808-67-8 ]
[ 1272973-64-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

16
[ 259808-67-8 ]
[ 1433990-39-6 ]

Reference： [1]Patent: US2013/116245,2013,A1
[2]Patent: EP2773638,2015,B1

17
[ 259808-67-8 ]
[ 1433990-40-9 ]

Reference： [1]Patent: US2013/116245,2013,A1
[2]Patent: EP2773638,2015,B1

18
[ 259808-67-8 ]
[ 1433990-41-0 ]

Reference： [1]Patent: US2013/116245,2013,A1
[2]Patent: EP2773638,2015,B1

19
[ 259808-67-8 ]
[ 1433990-42-1 ]

Reference： [1]Patent: US2013/116245,2013,A1
[2]Patent: EP2773638,2015,B1

20
[ 259808-67-8 ]
[ 1433990-43-2 ]

Reference： [1]Patent: US2013/116245,2013,A1

21
[ 259808-67-8 ]
[ 1433989-56-0 ]

Reference： [1]Patent: US2013/116245,2013,A1

22
[ 1429171-46-9 ]
[ 259808-67-8 ]
(2,2-dimethylpiperazin-1-yl)-[6-(2-fluoro-4-hydroxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl]methanone hydrochloride [ No CAS ]

Reference： [1]Patent: US2013/85128,2013,A1

23
[ 1429171-46-9 ]
[ 259808-67-8 ]
[ 1429171-67-4 ]

Yield	Reaction Conditions	Operation in experiment
58%		(a) 4-[6-(2-Fluoro-4-Hydroxy-phenyl)-3-methyl-1 -(tetrahydro-pyran-2-yl)-1 H-pyrazo- lo[3,4-b]pyridine-4-carbonyl]-3,3-dimethyl-piperazine-1 -carboxylic acid tert-butyl ester To a suspension of 6-(2-fluoro-4-Hydroxy-phenyl)-3-methyl-1 -(tetrahydro-pyran-2-yl)- 1 H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (150 mg) in dry dichloromethane (3 ml_), N,N-diisopropylethylamine (70 ??_), 2-bromo-1 -ethylpyridinium tetrafluoroborate (221 mg) and 1 -Boc-3,3-dimethylpiperazine (87 mg) were added. The solution was stirred for 30 min. Upon complete conversion, the solution is evaporated in vacuo and 3 ml_ of 30% sodium methoxide in methanol were added. The mixture was stirred for 30 min, the pH was adjusted to 5 by addition of 2M hydrochloric acid. Ethyl acetate was added and the organic layer was extracted with saturated sodium bicarbonate, 20% aqueous ammonium chloride solution and multiple times with water. The organic layer was dried over sodium sulfate and evaporated to dryness to give 132 mg (58%) of the title compound.LC/MS (Method LC1 ): Rt = 1 .34 min; m/z = 568.32 [M+H]+.
58%	With 2-bromo-1-ethylpyridin-1-ium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In dichloromethane; for 0.5h;	To a suspension of 6-(2-fluoro-4-Hydroxy-phenyl)-3-methyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (150 mg) in dry dichloromethane (3 mL), N,N-diisopropylethylamine (70 muL), 2-bromo-1-ethylpyridinium tetrafluoroborate (221 mg) and <strong>[259808-67-8]1-Boc-3,3-dimethylpiperazine</strong> (87 mg) were added. The solution was stirred for 30 min. Upon complete conversion, the solution is evaporated in vacuo and 3 mL of 30% sodium methoxide in methanol were added. The mixture was stirred for 30 min, the pH was adjusted to 5 by addition of 2M hydrochloric acid. Ethyl acetate was added and the organic layer was extracted with saturated sodium bicarbonate, 20% aqueous ammonium chloride solution and multiple times with water. The organic layer was dried over sodium sulfate and evaporated to dryness to give 132 mg (58%) of the title compound. LC/MS (Method LC1): Rt=1.34 min; m/z=568.32 [M+H]+.

Reference： [1]Patent: WO2013/45413,2013,A1 .Location in patent: Page/Page column 345-346
[2]Patent: US2013/85128,2013,A1 .Location in patent: Paragraph 1974; 1975; 1976

24
[ 39856-50-3 ]
[ 259808-67-8 ]
[ 1433990-38-5 ]

Yield	Reaction Conditions	Operation in experiment
27%	With tris-(dibenzylideneacetone)dipalladium(0); 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In 1,4-dioxane; at 120℃; for 24h;Inert atmosphere;	Example 125a tert-Butyl 3,3-Dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 125a A 100-mL single-neck round-bottomed flask equipped with a magnetic stirrer and a reflux condenser was charged with 5-bromo-2-nitropyridine (5.6 g, 28.0 mmol), <strong>[259808-67-8]tert-butyl 3,3-dimethyl-piperazine-1-carboxylate</strong> (3.0 g, 14.0 mmol), cesium carbonate (9.1 g, 28 mmol), and 1,4-dioxane (50 mL). After bubbling nitrogen through the resulting solution for 30 min, Binap (870 mg, 1.4 mmol) and tris(dibenzylideneacetone)dipalladium(0) (1.2 g, 1.4 mmol) were added. The reaction mixture was subjected to three cycles of vacuum/argon flush and stirred at 120 C. for 24 h. After this time the reaction was cooled to room temperature it was filtered and the filtrate was partitioned between ethyl acetate (200 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (3*50 mL). The combined organic layer was washed with brine (50 mL) and dried over sodium sulfate. The drying agent was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography eluting with 5:1 petroleum ether/ethyl acetate to afford 125a (1.27 g, 27%). LCMS: [M+H]+ 337.2.
27%	With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In 1,4-dioxane; at 120℃; for 24h;Inert atmosphere;	Example 190a tert-Butyl 3,3-Dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 190a A 100-mL single-neck round-bottomed flask equipped with a magnetic stirrer and a reflux condenser was charged with 5-bromo-2-nitropyridine (5.6 g, 28.0 mmol), tert-butyl 3,3-dimethyl-4-piperazine-1-carboxylate (3.0 g, 14.0 mmol), cesium carbonate (9.1 g, 28 mmol), and 1,4-dioxane (50 mL). After bubbling nitrogen through the resulting solution for 30 min, Binap (870 mg, 1.4 mmol) and tris(dibenzylideneacetone)-dipalladium(0) (1.2 g, 1.4 mmol) were added. The reaction mixture was subjected to three cycles of vacuum/argon flush and stirred at 120 C for 24 h. After this time the reaction was cooled to room temperature, filtered and the filtrate was partitioned between ethyl acetate (200 mL) and water (50 mL). The aqueous layer was separated and extracted with ethyl acetate (3 * 50 mL). The combined organic layers were washed with brine (50 mL) and dried over sodium sulfate. The drying agent was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica-gel column chromatography eluting with 5:1 petroleum ether/ethyl acetate to afford 190a (1.27 g, 27%). LCMS: [M+H]+ 337.2.

Reference： [1]Patent: US2013/116245,2013,A1 .Location in patent: Paragraph 0427
[2]Patent: EP2773638,2015,B1 .Location in patent: Paragraph 0688; 0689

25
[ 24036-63-3 ]
[ 259808-67-8 ]
[ 1443759-18-9 ]

Yield	Reaction Conditions	Operation in experiment
99%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 2h;	Intermediate 20: l-Cyclopropylmethyl-lH-[l ,2,4]triazole-3-carboxylic acid 20.1 : 3,3-Dimethyl-4-(l -phenyl- 1Eta-[ 1 ,2,4]triazole-3-carbonyl)-piperazine- 1 -carboxylic acid tert-butyl ester A mixture of 420 mg (2.22 mmol) l-phenyl-lH-[l ,2,4]triazole-3-carboxylic acid, 500 mg (2.22 mmol) 3,3-dimethyl-piperazine-l-carboxylic acid tert-butyl ester, 750 mg (2.22 mmol) TBTU and 500 mu (2.91 mmol) DIPEA in 5 mL DMF was stirred at RT for 2 h. The reaction mixture was poured into ice water. The precipitate was filtered off, taken up in EtOAc, dried over sodium sulfate, filtered and concentrated in vacuo. yield: 850 mg (99 %) ESI-MS: m/z = 386 (M+H)~ Rt(HPLC): 1.20 min (method 23)
99%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 2h;	20.1: 3,3-Dimethyl-4-(1-phenyl-1H-[1,2,4]triazole-3-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester A mixture of 420 mg (2.22 mmol) 1-phenyl-1H-[1,2,4]-triazole-3-carboxylic acid, 500 mg (2.22 mmol) <strong>[259808-67-8]3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong>, 750 mg (2.22 mmol) TBTU and 500 muL (2.91 mmol) DIPEA in 5 mL DMF was stirred at RT for 2 h. The reaction mixture was poured into ice water. The precipitate was filtered off, taken up in EtOAc, dried over sodium sulfate, filtered and concentrated in vacuo. yield: 850 mg (99%) ESI-MS: m/z=386 (M+H)- Rt(HPLC): 1.20 min (method 23)

Reference： [1]Patent: WO2013/87805,2013,A1 .Location in patent: Page/Page column 66
[2]Patent: US2013/158042,2013,A1 .Location in patent: Paragraph 0376; 0377; 0378; 0379; 0380; 0381

26
[ 259808-67-8 ]
[ 1443758-97-1 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

27
[ 259808-67-8 ]
[ 1443759-07-6 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

28
[ 259808-67-8 ]
[ 1443759-06-5 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

29
[ 259808-67-8 ]
[ 1443759-11-2 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

30
[ 259808-67-8 ]
[ 1443759-10-1 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

31
[ 259808-67-8 ]
[ 1443760-49-3 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

32
[ 259808-67-8 ]
[ 1443758-32-4 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

33
[ 501-53-1 ]
[ 259808-67-8 ]
[ 1400761-07-0 ]

Yield	Reaction Conditions	Operation in experiment
81%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃;	Intermediate 9: 2,2-Dimethyl-piperazine-l-carboxylic acid benzyl ester trifluoro acetate 9.1 : 2,2-Dimethyl-piperazine- 1 ,4-dicarboxylic acid 1 -benzyl ester 4-tert-butyl ester To a solution of 18.5 g (82.0 mmol) 3,3-dimethyl-piperazine-l-carboxylic acid tert-butyl ester in 150 mL DCM at RT was added 30.0 mL (174 mmol) DIPEA. The mixture was cooled with ice and a solution of 14.0 mL (93.2 mmol) benzyl chloroformate in 60 mL DCM was added drop wise. The reaction mixture was stirred at RT over night and quenched with saturated aqueous sodium bicarbonate solution. The product was extracted with DCM. The organic layers were combined, dried over sodium sulfate and concentrated in vacuo. Yield: 23.0 g (81%) ESI-MS: m/z = 249 (M-BOC+H)+ Rt(HPLC): 1.60 min (method 1)
81%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃;	9.1: 2,2-Dimethyl-piperazine-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester To a solution of 18.5 g (82.0 mmol) <strong>[259808-67-8]3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> in 150 mL DCM at RT was added 30.0 mL (174 mmol) DIPEA. The mixture was cooled with ice and a solution of 14.0 mL (93.2 mmol) benzyl chloroformate in 60 mL DCM was added dropwise. The reaction mixture was stirred at RT over night and quenched with saturated aqueous sodium bicarbonate solution. The product was extracted with DCM. The organic layers were combined, dried over sodium sulfate and concentrated in vacuo. Yield: 23.0 g (81%) ESI-MS: m/z=249 (M-BOC+H)+

Reference： [1]Patent: WO2013/87805,2013,A1 .Location in patent: Page/Page column 55; 56
[2]Patent: US2013/158042,2013,A1 .Location in patent: Paragraph 0265; 0266; 0267; 0268; 0269

34
[ 1292369-51-7 ]
[ 259808-67-8 ]
[ 1443759-35-0 ]

Yield	Reaction Conditions	Operation in experiment
30%		Intermediate 28 : (2,2-Dimethyl-piperazin- lyl)-[ 1 -(3-fluoro-phenyl)- 1Eta-[ 1 ,2,4]triazol-3yl]- methanone A mixture of 460 mg (2.22 mmol) l-(3-fluoro-phenyl)-lH-[l,2,4]triazole-3-carboxylic acid and 330 (2.49 mmol) l-chloro-N,N,2-trimethylpropylamine in 10 mL THF was stirred at RT for 30 min, 500 mg (2.22 mmol) 3,3-dimethyl-piperazine-l-carboxylic acid tert-butyl ester and 620 (4.45 mmol) TEA were added and the mixture was stirred at RT for 1 h. The solvent was removed by distillation and the residue was purified by HPLC. yield: 205 mg (30 %) ESI-MS: m/z = 304 (M+H)+ Rt(HPLC) : 1.24 min (method 3)
30%		Intermediate 28: (2,2-Dimethyl-piperazin-1yl)-[1-(3-fluoro-phenyl)-1H-[1,2,4]triazol-3yl]-methanone A mixture of 460 mg (2.22 mmol) 1-(3-fluoro-phenyl)-1H-[1,2,4]-triazole-3-carboxylic acid and 330 muL (2.49 mmol) 1-chloro-N,N,2-trimethylpropylamine in 10 mL THF was stirred at RT for 30 min, 500 mg (2.22 mmol) <strong>[259808-67-8]3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester</strong> and 620 muL (4.45 mmol) TEA were added and the mixture was stirred at RT for 1 h. The solvent was removed by distillation and the residue was purified by HPLC. yield: 205 mg (30%) ESI-MS: m/z=304 (M+H)+

Reference： [1]Patent: WO2013/87805,2013,A1 .Location in patent: Page/Page column 69; 70
[2]Patent: US2013/158042,2013,A1 .Location in patent: Paragraph 0415; 0416; 0417; 0418; 0419

35
[ 259808-67-8 ]
[ 1443755-80-3 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

36
[ 259808-67-8 ]
[ 1443757-50-3 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

37
[ 259808-67-8 ]
[ 1443759-05-4 ]

Reference： [1]Patent: WO2013/87805,2013,A1

38
[ 259808-67-8 ]
[ 1443757-61-6 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

39
[ 259808-67-8 ]
[ 1443758-98-2 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

40
[ 259808-67-8 ]
[ 1443757-72-9 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

41
[ 259808-67-8 ]
[ 1443757-81-0 ]

Reference： [1]Patent: WO2013/87805,2013,A1

42
[ 259808-67-8 ]
[ 1443758-99-3 ]
[ 1443759-00-9 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

43
[ 259808-67-8 ]
[ 1443759-01-0 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

44
[ 259808-67-8 ]
[ 1443759-03-2 ]

Reference： [1]Patent: WO2013/87805,2013,A1

45
[ 259808-67-8 ]
[ 1443759-14-5 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

46
[ 259808-67-8 ]
[ 1443759-16-7 ]

Reference： [1]Patent: WO2013/87805,2013,A1
[2]Patent: US2013/158042,2013,A1

47
[ 259808-67-8 ]
[ 1443759-04-3 ]

Reference： [1]Patent: US2013/158042,2013,A1

48
[ 259808-67-8 ]
[ 1443757-55-8 ]

Reference： [1]Patent: US2013/158042,2013,A1

49
[ 87-69-4 ]
[ 259808-67-8 ]
tert-butyl 3,3-dimethylpiperazine-1-carboxylate hemi-D,L-tartrate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
27.1 kg	In ethanol; at 20 - 52℃;Inert atmosphere;	2,2-dimethylpiperazine (1 1 .5 kg, 101 mol) was dissolved in ethanol (48.5 L) and the solution was cooled to approximately 9C. Di-tert-butyl dicarbonate (21 .9 kg, 100 mol) was dissolved in ethanol (41 .7 L). The solution of di-tertbutyl dicarbonate was added to the solution of dimethylpiperazine over a period of 2 h 30 min, keeping the temperature of the reaction below 15C. Ethanol (12.4 L) was added and the solution was stirred overnight at a temperature between 12-25C. The reaction was warmed to reflux and 75 L were distilled off. Ethanol (76 L) was added to the reaction and the solution was heated to 52C and transferred to a suspension of D,L-tartaric acid (7.5 kg, 50.0 mol) in ethanol (25.2 L), and warmed to 51 C. Ethanol (25.3 L ) was added and the reaction was kept at 20C overnight. The precipitate was filtered off and washed with ethanol (28.1 L). The solid was dried in a vacuum oven at 50C overnight to yield compound (XVIII) (27.1 kg, 93%) with 99% purity according to GC analysis.

Reference： [1]Patent: WO2014/96151,2014,A2 .Location in patent: Page/Page column 43

50
[ 259808-67-8 ]
[ 1416227-66-1 ]

Reference： [1]Patent: WO2014/96151,2014,A2

51
[ 259808-67-8 ]
1(d3),2,2-trimethylpiperazine bis-2,2,2-trifluoroacetate [ No CAS ]

Reference： [1]Patent: WO2014/96151,2014,A2

52
[ 259808-67-8 ]
4-((1R,3S)-6-chloro-3-(phenyl-d5)-indan-1-yl)-1(d3),2,2-trimethylpiperazine [ No CAS ]

Reference： [1]Patent: WO2014/96151,2014,A2

53
[ 259808-67-8 ]
[ 1416227-74-1 ]

Reference： [1]Patent: WO2014/96151,2014,A2

54
[ 259808-67-8 ]
[ 1616383-05-1 ]

Reference： [1]Patent: WO2014/96151,2014,A2

55
[ 1722-12-9 ]
[ 259808-67-8 ]
tert-butyl 3,3-dimethyl-4-(pyrimidin-2-yl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium fluoride; triethylamine; In N,N-dimethyl-formamide; at 80 - 140℃; for 25h;Inert atmosphere; Microwave irradiation;	Tert-butyl 3,3-dimethylpiperazine-1-carboxylate (CAS 259808-67-8, 300 mg, 1.40 mmol), 2- chloropyrimidine (CAS 1722-12-9, 240 mg, 2.10 mmol), potassium fluoride (122 mg, 2.10 mmol) and TEA (0.389 mL, 2.80 mmol) were dissolved in DMF (3 mL). After flushing with argon, the solution was heated in a microwave reactor for 3 h at 80C, 6h at 100C, 6 h at 120C and 10 h at 140C.After cooling to rt the crude mixture was extracted with EtOAc (2x10mL) and water. The combined organic phases were washed with 1M HCI (aq), dried over Mg504 and evaporated to give crude tert-butyl 3,3-dimethyl-4-(pyrimidin-2-yl)piperazine-1- carboxylate.

Reference： [1]Patent: WO2014/184248,2014,A2 .Location in patent: Page/Page column 49

56
6-(4-fluorophenyl)-8-(1-methylcyclopropyl)imidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[6-(4-fluorophenyl)-8-(1-methylcyclopropyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 2h;	6-(4-Fluorophenyl)-8-( 1 -methylcyclopropyl)imidazo[ 1 ,2-b]pyridazine-2- carboxylic acid (150 mg, 0.48 mmol) was dissolved in DMF (4.5 mL) and HATU (238 mg, 0.63 mmol), <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (113.6 mg, 0.53 mmol) and DIPEA (249 mg, 336 .iL, 1.93 mmol) were added. The solution was stirred at r. t. for 3h and then aqueous NH4C1 was added and the aqueous phase was extracted twice with EtOAc. The combined organic layers were washed with iN HC1 aqueous, saturated aqueous NaHCO3 and brine, dried over anhydrous Mg504, filtered and the filtrate evaporated under reduced pressure affording the title compound (245 mg, quantitative) as a yellow solid which was used in the subsequent step without further purification. LC-MS: mlz = 508.17 (M+Hj.

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00288

57
6-chloro-8-isopropylimidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-(6-chloro-8-isopropylimidazo[1,2-b]pyridazine-2-carbonyl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
51%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; for 1h;	6-Chloro-8-isopropyl-imidazo [1 ,2-b]pyridazine-2-carboxylic acid (2.3 g, 9.5 mmol) was solubilized in N,N-dimethylformamide (37.8 mL) and DIPEA (3.06 g, 4.12 mL, 23.65 mmol). HATU (3.95 g, 10.4 mmol) was added followed by tert-butyl 3,3- dimethylpiperazine-1-carboxylate (2.23 g, 10.4 mmol). The solution was allowed to stir for 1 hour. Upon completion, a saturated aqueous solution of NH4C1 was added to the reaction mixture. The layers were partitioned and the aqueous layer was extracted 3 times with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by flash chromatography using 0-100% ethyl acetate: hexanes to afford the title compound (2.13 g, 51% yield). ?HNMR (400 MHz, Chloroform-d) oe 8.27 (s, 1H), 6.89 (s, 1H), 4.31 -4.17 (m, 2H), 3.67 - 3.45 (m, 5H), 1.63 - 1.58 (m, 6H), 1.51 - 1.46 (m, 9H), 1.44 - 1.37 (m, 6H). LCMS: mlz = 436.45 (M+Hj

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00260

58
6-(4-fluorophenyl)-8-isopropylimidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[6-(4-fluorophenyl)-8-isopropylimidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
58 mg	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	To a solution of Intermediate E (59 mg, 0.20 mmol) in DMF (3 mL) were added <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (50.7 mg, 0.24 mmol), HATU (97.4 mg, 0.26 mmol) and DIPEA (51 mg, 69 .iL, 0.39 mmol) and the resulting mixture was stirred at rt ON. The reaction mixture was then diluted with EtOAc, washed with water and brine consecutively, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by flash chromatography eluting with EtOAc/Hexanes 0-50% in 20 CV to obtain tert-butyl 4- [6-(4-fluorophenyl)-8-isopropyl-imidazo[ 1 ,2-b]pyridazine-2-carbonyl] - 3,3-dimethyl-piperazine-1-carboxylate (58 mg) as a white solid. ?H NMR (400 MHz, CDC13) oe 8.33 (s, 1H), 8.11 -7.87 (m, 2H), 7.24-7.10 (m, 3H), 4.28 (s, 2H), 3.77 -3.43 (m, 5H), 1.61 (s, 6H), 1.51 - 1.40 (m, 15H). LC-MS: 497.5 (M+H).

Reference： [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 121 - 126
[2]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00229

59
8-cyclopropyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[8-cyclopropyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		j00268j 8-Cyclopropyl-6-(4-fluorophenyl)imidazo[ 1 ,2-b]pyridazine-2-carboxylic acid (80 mg, 0.27 mmol) was dissolved in DMF (3.4 mL) and DIPEA (121.7 mg, 164 tL, 0.94 mmol) followed by <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (69.20 mg, 0.3229 mmol) were successively added at r. t. After 2 mi HATU (153.5 mg, 0.40 mmol) was added and the reaction mixture was stirred at r.t. ON. Water was added and the reaction mixture and the mixture was extracted with EtOAc. The resulting organic phase was washed twice with a 1:1 mixture of water and brine, dried over anhydrous Mg504, filtered and evaporated under reduced pressure. The resulting crude product was used as such in the next reaction. LC-MS:mlz = 494.26 (M+Hj.

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00268

60
8-ethyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[8-ethyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
235 mg	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	To a solution of Intermediate H (190 mg, 0.67 mmol) in DMF (3 mL) were added <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (171.3 mg, 0.80 mmol), HATU (329.2 mg, 0.87 mmol) and DIPEA (232 tL, 1.3 mmol) and the mixture was stirred at rt ON. The reaction mixture was then diluted with EtOAc, washed with water and brine consecutively, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by flash chromatography eluting with EtOAc/hexanes 0-50% in 20 CV to obtain tertbutyl 4- [8-ethyl-6-(4-fluorophenyl)imidazo[ 1 ,2-b]pyridazine-2-carbonyl] -3,3 -dimethylpiperazine-1-carboxylate (235 mg) as a white solid. ?H NMR (400 MHz, CDC13) oe 8.32 (s, 1H), 8.04-7.86 (m, 2H), 7.26 (s, 1H), 7.22-7.11 (m, 2H), 4.39-3.92 (m, 2H), 3.73 -3.40 (m, 4H), 3.09 (m, 2H), 1.65 - 1.59 (m, 6H), 1.50 - 1.40 (m, 12H). LC-MS: 482.5 (M+H).

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00226

61
8-(tert-butyl)-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-(8-(tert-butyl)-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
97.5%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	General procedure: The appropriate carboxylic acid (1.0 equiv) is dissolved in DMF or NMP (0.15 to 0.3 M) before HATU (1.1 to 1.5 equiv), the corresponding amine (1.1-1.2 equiv) and Huenig? s base (2.5 to 3.5 equiv) are added. The mixture is stirred at room temperature between 45 mm. and 16h. Either one of these 4 work-up procedures can be employed j00237j The intermediate was prepared according to general procedure 1 using Intermediate P (1.0 equiv), DMF (0.3M), HATU (1.1 equiv), tert-butyl 3,3- dimethylpiperazine-1-carboxylate (1.1 equiv) and Huenig?s base (2.5 equiv) affording tertbutyl 4-(8-(tert-butyl)-6-(4-fluorophenyl)imidazo [1 ,2-b]pyridazine-2-carbonyl)-3 ,3 - dimethylpiperazine-1-carboxylate (47.6g, 93.5 mmol, 97.5%). ?H NMR (400 MHz, DMSOd6) oe 8.52 (s, 1H), 8.18 -8.11 (m, 2H), 7.49 (s, 1H), 7.45 -7.37 (m, 2H), 4.17-4.05 (m, 2H), 3.59 - 3.44 (m, 4H), 1.59 (s, 9H), 1.50 (s, 6H), 1.43 (s, 9H). LC-MS: 510.13 (M+H), retention time: 2.18 minutes using method C.

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00237

62
8-(tert-butyl)-6-(4,4-difluorocyclohexyl)imidazo[1,2-b]pyridazine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[8-tert-butyl-6-(4,4-difluorocyclohexyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
96.85%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	The product was prepared according to General Procedure 1 using 8-tert-butyl- 6-(4,4-difluorocyclohexyl)imidazo [1 ,2-b]pyridazine-2-carboxylic acid (500 mg, 1.482 mmol), DMF (10 mL), HATU (845.3 mg, 2.223 mmol), Huenig?s base (775 tL, 4.449 mmol) and <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (476.4 mg, 2.223 mmol Purification by flash chromatography on silica gel was carried out under standard condition to afford title compound tert-butyl 4-[8-tert-butyl-6-(4,4-difluorocyclohexyl)imidazo [1 ,2-b]pyridazine-2- carbonyl]-3,3-dimethyl-piperazine-1-carboxylate (766 mg, 1.435 mmol, 96.85%) as a white solid. ?H NMR (400 MHz, Chloroform-cl) oe 8.23 (s, 1H), 6.72 (s, 1H), 4.31 (t, J= 6.3 Hz, 2H), 3.68-3.34 (m, 4H), 2.81 (t, J= 10.9 Hz, 1H), 2.24 (dt, J= 12.3, 7.2 Hz, 2H), 2.12 -1.72 (m, 6H), 1.59 (s, 6H), 1.52 (t, J= 1.9 Hz, 9H), 1.47 (d, J= 1.7 Hz, 9H). LC-MS: 534.26 (M+Hj.

Reference： [1]Patent: WO2015/48245,2015,A1 .Location in patent: Paragraph 00242

63
[ 823-62-1 ]
[ 259808-67-8 ]
tert-butyl 4-(5-amino-6-chloro-1,2,4-triazin-3-yl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
13%	With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 155℃; for 12h;Microwave irradiation;	A vial was charged with 5-amino-3,6-dichloro-l,2,4-triazine (736 mg, 4.46 mmol), diisopropylethylamine (2.0 mL, 11.48 mmol), tert-butyl 2-(3,3-dimethylpiperazin-l- yl)acetate (1.0875 g, 4.52 mmol) in dioxane (8 mL). The mixture was heated at 155 C for 12 h using microwave. The mixture was concentrated to remove all of solvent. The residue was treated with saturated sodium bicarbonate solution, extracted with dichloromethane (4 x 50 mL). The combined organic solution was washed with brine, dried over anhydrous sodium sulfate, concentrated. The residue was separated with flash column chromatography on silica gel using 1-10% methanol in dichloromethane, and 30-100% ethyl acetate/Hexane to afford product (201.8 mg) in 13% yield. NMR (500 MHz, Chloroform-*/) delta 5.12 (s, 2H), 4.06 - 4.02 (m , 2H), 3.52 - 3.46 (m, 2H), 1.50 (s, 6H), 1.44 (s, 9H). MS for C 14H23CIN6O2: 343.2 (MH+).

Reference： [1]Patent: WO2015/92819,2015,A2 .Location in patent: Paragraph 0721; 0722

64
[ 259808-67-8 ]
(4-(5-((5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methyl acetate [ No CAS ]

Reference： [1]Patent: EP2773638,2015,B1
[2]Patent: EP2773638,2015,B1

65
[ 259808-67-8 ]
2-(4-(5-((5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one [ No CAS ]

Reference： [1]Patent: EP2773638,2015,B1
[2]Patent: EP2773638,2015,B1

66
7-methoxy-8-(1-methyl-1H-pyrazol-3-yl)-1-(thiophen-3-yl)-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
4-[7-methoxy-8-(1-methyl-1H-pyrazol-3-yl)-1-thiophen-3-yl-1,4-dihydro-chromeno[4,3-c]pyrazole-3-carbonyl]-3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
37.2%	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃;	A mixture of 7-methoxy-8- (1-methyl-1H-pyrazol-3-yl) -1- (thiophen-3-yl) -1, 4-dihydrochromeno [4, 3-c] pyrazole-3-carboxylic acid (50 mg, 0.123 mmol) , HATU (51 mg, 0.135 mmol) , tert-butyl 3, 3-dimethylpiperazine-1-carboxylate (34 mg, 0.135 mmol) and DIPEA (48 mg, 0.369 mmol) in DMF (3 ml) was was stirred at RT overnight. Then the mixture was purified by Combi-Flash (mobile phase: acetonitrile/water (10 mM NH4HCO3) to afford tert-butyl 4- (7-methoxy-8- (1-methyl-1H-pyrazol-3-yl) -1- (thiophen-3-yl) -1, 4-dihydrochromeno [4, 3-c] pyrazole-3-carbonyl) -3, 3-dimethylpiperazine-1-carboxylate (55 mg, 37.2) as a white solid. LCMS m/z605 [M+H] +.

Reference： [1]Patent: WO2015/196759,2015,A1 .Location in patent: Paragraph 00335; 00336

67
7-bromo-5-chlorofuro[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-(7-bromo-5-chlorofuro[3,2-b]pyridine-2-carbonyl)-3,3-dimethyl-piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
86.26%	With 4-methyl-morpholine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; In N,N-dimethyl-formamide; at 20℃; for 0.5h;	To a solution of 7-bromo-5-chloro-furo[3,2-b]pyridine-2-carboxylic acid (200 mg, 0.723 mmol) and <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (164.3 mg, 0.767 mmol) in DMF (2.13 mL) was added N-methyl morpholine (329.2 mg, 357.8 muL, 3.26 mmol) at ambient temperature. T3P (575.4 mg, 0.904 mmol) 50% W/W in DMF was added dropwise and the solution was stirred at room temperature for 30 minutes. NaHCO3 was added and the aqueous phase was extracted with EtOAc 3 times. The combined organic phase was washed with sat aq. ammonium chloride and brine, dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by silica gel chromatography affording the title compound, tert-butyl 4-(7-bromo-5-chloro-furo[3,2- b]pyridine-2-carbonyl)-3,3-dimethyl-piperazine-1-carboxylate (295 mg, 0.6240 mmol, 86.26%). ESI-MS m/z calc.471.05606, found 472.24 (M+1)+; Rt: 2.05 min using Method C

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Page/Page column 287; 288

68
7-chloro-5-(4-fluorophenyl)furo[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[7-chloro-5-(4-fluorophenyl)furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 3h;	Scheme 2 [00253] 7-Chloro-5-(4-fluorophenyl)furo[3,2-b]pyridine-2-carboxylic acid (Intermediate A) (390 mg, 1.34 mmol) was dissolved in DMF (6 mL) before HATU (661 mg, 1.74 mmol), <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (287 mg, 1.34 mmol) and Huenig's base (932 muL, 5.35 mmol) were added. The solution was stirred at room temperature for 3h, and then saturated aqueous NH4Cl is added. The aq. phase was extracted twice with EtOAc. The combined organic phase was washed with 1N HCl, saturated aqueous NaHCO3 and brine. The organic phase was then dried over MgSO4, filtered and the filtrate evaporated under reduced pressure. The crude product was used in the subsequent step without further purification. tert-Butyl 4-[7-chloro-5-(4- fluorophenyl)furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethyl-piperazine-1-carboxylate (170 mg, 24% yield). ESI-MS m/z calc.487.16742, found 488.39 (M+1)+; Retention time: 2.16 minutes using method C

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Paragraph 00253

69
5-(4-fluorophenyl)-7-isopropylfuro[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[5-(4-fluorophenyl)-7-isopropylfuro[3,2-b]pyridine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 72h;	Scheme 6 Step I: tert-Butyl 4-[5-(4-fluorophenyl)-7-isopropyl-furo[3,2-b]pyridine-2-carbonyl]- 3,3-dimethyl-piperazine-1-carboxylate The product was prepared according to General Procedure 1 using Intermediate D (750 mg, 2.51 mmol), HATU (1.24 g, 3.26 mmol), DMF (12 mL), Huenig's base (1.31 mL, 7.52 mmol) and tert-butyl 3,3-dimethylpiperazine- 1-carboxylate (591 mg, 2.76 mmol) affording the title compound. tert-Butyl 4-[5-(4- fluorophenyl)-7-isopropyl-furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethyl-piperazine-1- carboxylate (1.24 g, 100% yield). An aliquot of the crude product was purified by mass- directed reverse phase HPLC affording the title compound, the remaining product was used in the subsequent step without further purification.1H NMR (400 MHz, DMSO-d6) 8.23 - 8.14 (m, 2H), 7.88 (s, 1H), 7.50 (s, 1H), 7.33 (t, J = 8.9 Hz, 2H), 3.86 (s, 2H), 3.58 - 3.39 (m, 5H), 1.49 (s, 6H), 1.42 (d, J = 7.7 Hz, 15H). ESI-MS m/z calc.495.25333, found 496.79 (M+1)+; Retention time: 2.02 minutes using method C General Procedure 1: Amide Formation The appropriate carboxylic acid (1.0 equiv) is dissolved in DMF or NMP (0.03 to 0.4M) before HATU (1.1 to 1.5 equiv), or T3P (1 to 5 equiv) the corresponding amine (1.0 to 1.5 equiv) and Huenig?s base (3.0 to 5.0 equiv) are added (the addition order of the reagents may vary) The mixture is stirred at room temperature for 45 min. to 72h. Either one of these 3 work-up procedures can be employed: 1. Water or aq. ammonium chloride is added and the aq. phase is extracted with EtOAc. The combined organic phase is washed with brine, dried over MgSO4, filtered and the filtrate evaporated under reduced pressure affording the title compound which is used in the subsequent step without further purification. 2. Water or aq. ammonium chloride is added and the aq. phase is extracted with EtOAc. The combined organic phase is washed with 1N HCl, sat. aq. NaHCO3 and brine, dried over Na2SO4, filtered and the filtrate evaporated under reduced pressure affording the title compound which is used in the subsequent step without further purification. 3. The volatiles are removed under reduced pressure and the residue is purified by flash chromatography on silica gel or by mass-directed reverse phase HPLC, affording the title compound

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Page/Page column 120; 139; 140

70
2-(4-fluorophenyl)-4-isopropylfuro[3,2-d]pyrimidine-6-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[2-(4-fluorophenyl)-4-isopropylfuro[3,2-d]pyrimidine-6-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
72%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	To a solution of Intermediate M (27 mg, 0.090 mmol) in DMF (1.5 mL) were added <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (30 mg, 0.13 mmol), HATU (51 mg, 0.13 mmol) and Huenig?s base (63 muL, 0.36 mmol) and the solution was stirred at room temperature overnight. The volatiles were removed under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with 0-25% EtOAc: Hexanes affording the title compound. tert-Butyl 4-[2-(4-fluorophenyl)-4-isopropyl- furo[3,2-d]pyrimidine-6-carbonyl]-3,3-dimethyl-piperazine-1-carboxylate (32 mg, 72% yield).1H NMR (400 MHz, Chloroform-d) 8.63 - 8.37 (m, 2H), 7.27 (s, 1H), 7.19 - 6.95 (m, 2H), 3.79 (dd, J = 6.6, 4.8 Hz, 2H), 3.66 - 3.40 (m, 5H), 1.59 (s, 6H), 1.47 (d, J = 6.5 Hz, 15H)

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Page/Page column 245; 246

71
7-(tert-butyl)-5-(4,4-dimethylcyclohexyl)furo[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-(7-(tert-butyl)-5-(4,4-dimethylcyclohexyl)furo[3,2-b]pyridine-2-carbonyl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 3h;	<strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (19.90 g, 92.86 mmol) and (2,2-dimethylpiperazin-1-yl)methanone hydrochloride (Intermediate II) (27.87 g, 84.60 mmol) were dissolved in DMF (300 mL) before HATU (35.45 g, 93.23 mmol) and DIPEA (27.72 g, 37.36 mL, 214.5 mmol) were added. The solution was stirred at room temperature for 3h, and then water was added dropwise. The aq. phase was extracted three times with EtOAc. The combined organic phase was washed with water and brine. The organic phase was then dried over Na2SO4, filtered and the filtrate evaporated under reduced pressure. The crude product was purified passing through a pad of silica gel (25%-33% EtOAc/hexanes affording the title product (34.28 g, 91% yield) as a yellow orange foamy solid, which was used directly in the next step. 1H NMR (400 MHz, Chloroform-d) 7.34 (s, 1H), 7.06 (s, 1H), 3.84 (dd, J = 6.6, 4.8 Hz, 2H), 3.67 - 3.45 (m, 4H), 2.71 (tt, J = 10.3, 5.5 Hz, 1H), 1.85 - 1.77 (m, 4H), 1.77 - 1.71 (m, 1H), 1.57 - 1.51 (m, 2H), 1.49 (s, 9H), 1.49 (s, 9H), 1.43 - 1.31 (m, 3H), 1.01 (s, 3H), 0.97 (s, 3H). ESI-MS m/z calc.525.3567, found 526.61 (M+1)+; Retention time: 3.15 minutes using method A
91%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 3h;	<strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (19.90 g, 92.86 mmol) and (2,2- dimethylpiperazin-1-yl)methanone hydrochloride (Intermediate C) (27.87 g, 84.60 mmol) are dissolved in DMF (300 mL) before HATU (35.45 g, 93.23 mmol) and DIPEA (27.72 g, 37.36 mL, 214.5 mmol) are added. The solution is stirred at room temperature for 3h, and then water is added dropwise. The aq. phase is extracted three times with EtOAc. The combined organic phase is washed with water and brine. The organic phase is then dried over Na2SO4, filtered and the filtrate evaporated under reduced pressure. The crude product is purified passing through a pad of silica gel (25%-33% EtOAc/hexanes affording the title product (34.28 g, 91% yield) as a yellow orange foamy solid, which is used directly in the next step. 1H NMR (400 MHz, Chloroform-d) 6 7.34 (s, 1H), 7.06 (s, 1H), 3.84 (dd, J = 6.6, 4.8 Hz, 2H), 3.67 - 3.45 (m, 4H), 2.71 (tt, J = 10.3, 5.5 Hz, 1H), 1.85 - 1.77 (m, 4H), 1.77 - 1.71 (m, 1H), 1.57 - 1.51 (m, 2H), 1.49 (s, 9H), 1.49 (s, 9H), 1.43- 1.31 (m, 3H), 1.01 (s, 3H), 0.97 (s, 3H). ESI-MS m/z calc. 525.3567, found 526.61 (M+1) Retention time: 3.15 minutes using method A.

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Page/Page column 193; 194
[2]Patent: WO2018/57588,2018,A1 .Location in patent: Paragraph 0223

72
7-tert-butyl-5-(4,4-dichlorocyclohexyl)furo[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[7-tert-butyl-5-(4,4-dichlorocyclohexyl)furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
64%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide;	To a solution of <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (152.4 mg, 0.711 mmol) in dry DMF (2.5 mL) was added 7-tert-butyl-5-(4,4-dichlorocyclohexyl)furo[3,2- b]pyridine-2-carboxylic acid (240 mg, 0.6482 mmol), DIPEA (212.3 mg, 286.1 muL, 1.64mmol) and HATU (271.6 mg, 0.7143 mmol). After 30 min, H2O (20 mL) was added. The mixture was extracted with EtOAc (X3), dried (MgSO4), and the solvent was removed under reduced pressure to afford tert-butyl 4-[7-tert-butyl-5-(4,4- dichlorocyclohexyl)furo[3,2- b]pyridine-2-carbonyl]- 3,3-dimethyl-piperazine-1- carboxylate (235 mg, 64%). To the N-Boc intermediate in dioxane (4.94 mL) was added HCl in dioxane (810.2 muL 4 M, 3.24 mmol). The mixture was stirred for 24 h, and MeOH (0.05 mL) was added and stirring continued for 3 h. The solvent was removed in vacuo to give 7-tert-butyl-5-(4,4- dichlorocyclohexyl)furo[3,2-b]pyridin-2-yl]-(2,2- dimethylpiperazin-1-yl)methanone (Hydrochloride salt) (210 mg, 101%). ESI-MS m/z calc.465.19498, found 466.3 (M+1)+; Rt: 1.27 minutes using Method C

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Page/Page column 211; 214

73
7-tert-butyl-5-(4,4-difluorocyclohexyl)furo[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[7-tert-butyl-5-(4,4-difluorocyclohexyl)furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
66%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide;	7-tert-butyl-5-(4,4-difluorocyclohexyl)furo[3,2-b]pyridine-2-carboxylic acid (910 mg, 2.697 mmol) and <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (578.0 mg, 2.697 mmol) was dissolved in DMF (3.3 mL). HATU (1.33 g, 3.51 mmol) and DIPEA (1.64 mL, 9.44 mmol) were successively added at RT. The reaction mixture was stirred overnight. EtOAc along with water were added. The phases were separated, and concentrated in vacuo to afford the title compound (950 mg, 66%). ESI-MS m/z calc. 533.3065, found 534.21. Rt: 2.48 min using Method C

Reference： [1]Patent: WO2016/154075,2016,A1 .Location in patent: Paragraph 00410

74
[ 259808-67-8 ]
C₁₃H₁₇BrN₄ [ No CAS ]

Reference： [1]Patent: WO2017/7700,2017,A1

75
[ 259808-67-8 ]
C₁₄H₁₉BrN₄O₂S [ No CAS ]

Reference： [1]Patent: WO2017/7700,2017,A1

76
[ 259808-67-8 ]
2,2-dimethyl-1-(methylsulfonyl)piperazine hydrochloride [ No CAS ]

Reference： [1]Patent: WO2017/7700,2017,A1

77
[ 259808-67-8 ]
C₁₄H₁₉BrN₄O₂S [ No CAS ]

Reference： [1]Patent: WO2017/7700,2017,A1

78
[ 259808-67-8 ]
1-methanesulfonyl-2,2-dimethyl-4-[7-(trifluoromethyl)imidazo[1,5-a]pyridin-5-yl]piperazine [ No CAS ]

Reference： [1]Patent: WO2017/7700,2017,A1

79
[ 76-05-1 ]
[ 259808-67-8 ]
(x)C₂HF₃O₂*C₆H₁₄N₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; at 0 - 20℃; for 3h;	A solution of 21 (200 mg, 0.93 mmol) in CH2C12 (5.0 mL) was charged with TFA (1.0 mL) at 0C. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated in vacuo to afford 22 [100 mg (cmde), 94%j as a liquid.

Reference： [1]Patent: WO2017/7700,2017,A1 .Location in patent: Page/Page column 121

80
C₈H₃Cl₂FN₂ [ No CAS ]
[ 259808-67-8 ]
C₁₉H₂₄ClFN₄O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
32%	With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 20℃; for 2h;	General procedure: In a 1 L round-bottom flask with a magnetic stir bar, compound 7 (46 g, 0.2014 mol, 1.0 eq.) was diluted in DIEA (41.64 mL, 0.2416 mol, 1.2 equivalents) and THF (700 mL). Solid N-Boc piperazine (39.38 g, 0.2114 mol, 1.05 eq.) was slowly added in portions. A mild exothermic reaction was observed. The reaction mixture was allowed to stir at room temperature for 2 hours then was quenched with saturated NaCl solution (100 mL), water (400 mL), and EtOAc (500 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 200 mL). The combined organic layers were dried (Na2SO4) and concentrated to give a gray solid. The crude solid was stirred in 2:1 TBME/hexanes (300/150 mL) overnight. The solids were filtered then washed with hexane (250 mL) to recover 52 g of impure product. The TBME/hexanes slurry was repeated to recover 46 g (59%) of compound 8. All remaining impure material was combined and purified via silica gel chromatography (4:1 hexane/EtOAc) to recover another 11.2 g (14%) of 8 for a total combined yield of 57.2 g (74%).

Reference： [1]Patent: WO2017/100546,2017,A1 .Location in patent: Page/Page column 51; 52; 54

81
4-bromomethyl-pyridine-2-yl amine hydrobromide [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[(2-aminopyridin-4-yl)methyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 14h;	To a stirred solution of 4-(bromomethyl)pyridin-2-amine hydrobromide (2.50 g, 9.33 mmol) in DMF (30 mL) was added potassium carbonate (5.16 g, 37.3 mmol) and <strong>[259808-67-8]tert-butyl 3,3-dimethylpiperazine-1-carboxylate</strong> (2.409, 11.2 mmol). The mixture was stirred at r.t. for 14 h. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with half-saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuum. Aminophase-silicagel chromatography followed by silicagel chromatography gave 2.20 g (74 % yield) of the title compound.LC-MS (Method 2): Rt = 1.16 mm; MS (ESIpos): m/z = 321 [M+H]1H-NMR (400 MHz, DMSO-d6) 6 [ppm]: 1.004 (9.22), 1.027 (0.55), 1.042 (0.53), 1.390 (16.00),2.276 (0.67), 3.126 (0.69), 3.335 (3.19), 5.788 (1.25), 6.414 (0.98), 6.423 (0.68), 6.435 (0.58),7.775 (0.78), 7.777 (0.73), 7.788 (0.73), 7.790 (0.73).

Reference： [1]Patent: WO2017/102091,2017,A1 .Location in patent: Page/Page column 365

82
[ 352-34-1 ]
[ 259808-67-8 ]
tert-butyl 4-(4-fluorophenyl)-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With bis(tri-t-butylphosphine)palladium(0); sodium t-butanolate; In toluene; at 110℃; for 2h;Inert atmosphere;	Step 1 : tert-butyl 4-(4-fluorophenyl)-3,3-dimethyl-piperazine-l-carboxylate [00400] A32-1 (200.0 mg, 0.933 mmol, 1.00 eq), A32-2 (310.8 mg, 1.40 mmol, 0. 16 mL, (1153) 1.50 eq), f-BuONa (179.4 mg, 1.87 mmol, 2.00 eq) and bis(tri-tertbutylphosphine) Palladium(O) (47.69 mg, 0.093 mmol, 0. 10 eq) were taken up into toluene (6.00 mL). The reaction mixture was stirred at 1 10 C for 2 hour under N2. LCMS and TLC (Petroleum ether: Ethyl acetate=10/l) showed desired compound was found and the starting material was consumed completely. The reaction mixture was concentrated to give a crude product. The residue was purified by Prep- TLC (Petroleum ether: Ethyl acetate= 10/1) to give the A32-3 (260.0 mg, 0.776 mmol, 83. 1 1% yield, 92% purity) as a yellow oil. LCMS (ESI): RT =0.630 min, mass calcd. for C17H25FN2O2 308.19, m/z found 308.9 [M+H]+

Reference： [1]Patent: WO2017/58716,2017,A1 .Location in patent: Paragraph 00400

83
[ 259808-67-8 ]
1-(4-fluorophenyl)-2,2-dimethylpiperazine hydrochloride [ No CAS ]

Reference： [1]Patent: WO2017/58716,2017,A1

84
[ 259808-67-8 ]
2-(4,4-dimethylcyclohexyl)sulfonyl-7-[4-(4-fluorophenyl)-3,3-dimethylpiperazin-1-yl]sulfonylfluoren-9-one [ No CAS ]

Reference： [1]Patent: WO2017/58716,2017,A1

85
[ 259808-67-8 ]
2-(4,4-dimethylcyclohexyl)sulfonyl-7-[4-(4-fluorophenyl)-3,3-dimethylpiperazin-1-yl]sulfonylfluoren-9-one oxime [ No CAS ]

Reference： [1]Patent: WO2017/58716,2017,A1

86
methyl 4-[2-[4-[[2-[[3-(chloromethyl)benzoyl]amino]-4,5,6,7-tetrahydrobenzothiophene-3-carbonyl]amino]-2,6-difluorophenyl]ethyl]benzoate [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[[3-[[3-[[3,5-difluoro-4-[2-(4-methoxycarbonylphenyl)ethyl]phenyl]carbamoyl]-4,5,6,7-tetrahydrobenzothiophen-2-yl]carbamoyl]phenyl]methyl]-3,3-dimethylpiperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
69%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 110℃; for 4h;Microwave irradiation;	A 2OmL microwave reaction vessel is charged with methyl 4-42-[44[2-4[3- (chloromethyl)benzoyl]amino14, 5,6,7tetrahydrobenzothiophene3 -carbonyi1aminoi2,6 difiuoro-phenyI]ethyijhenzoate (1 .85 g, 2.97 mmol), tert-hutyi 3,3dimethylpiperazine-icarboxylate (0.91 g, 416 mmol), and DllEA (207 mL, 11.9 mmol)in 15 mL of ACN. The resulting yellow suspension is heated in a BIOTAGE Initiator microwave synthesizer at 110C for 4 hr. The reaction mixture is concentrated in vacuo and the residue is partitionedbetween 5% aqueous NaHCO3 (150 mL) and DCM (50 ml,). The organic layer is separated, the aqueous layer is extracted with DCM (2 x 25 rnL). The combined organic layers arewashed with saturated aqueous NaC1 (50 ml.), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The resulting residue is purified by chromatography over silica, eluting with a gradient of 0 100% of a mixture of 9: 1 I)CM/acetone in hexane, to afford the title compound as a yellow solid (163 g, 69% yield) after solvent evaporation. ?HMvR(400.i MHz, DMSOd6) oe 1.04 (s, 6H), 1.38 (s, 9H),1.81-1.74 (m, 4H), 2.28 (t, J 5.0 Hz, 2H), 2.70

Reference： [1]Patent: WO2018/34883,2018,A1 .Location in patent: Page/Page column 35; 36; 65; 66

87
[ 109-04-6 ]
[ 259808-67-8 ]
2,2-dimethyl-1-(2-pyridyl)piperazine [ No CAS ]

Reference： [1]Patent: US2018/127370,2018,A1

88
7-tert-butyl-5-(4-chloro-3-fluorophenyl)furo[3,2-b]pyridine-2-carboxylic acid [ No CAS ]
[ 259808-67-8 ]
tert-butyl 4-[7-tert-butyl-5-(4-chloro-3-fluorophenyl)furo[3,2-b]pyridine-2-carbonyl]-3,3-dimethyl-piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃;	General procedure: The appropriate carboxylic acid (1.0 equiv) is dissolved in DMF or NMP (0.03 to 0.4M) before HATU (1.1 to 1.5 equiv), or T3P (1 to 5 equiv) the corresponding amine (1.0 to 1.5 equiv) and Hunig?s base (3.0 to 5.0 equiv) are added (the addition order of the reagents may vary) The mixture is stirred at room temperature for 45 mm. to 72h. Any one of these 3 work-up procedures can be employed:1. Water or aq. ammonium chloride is added and the aq. phase is extracted with EtOAc. The combined organic phase is washed with brine, dried over MgSO4, filtered and the filtrate evaporated under reduced pressure affording the title compound which is used in the subsequent step without further purification.2. Water or aq. ammonium chloride is added and the aq. phase is extracted with EtOAc. The combined organic phase is washed with iN HCI, sat. aq. NaHCO3 and brine, dried over Na2SO4, filtered and the filtrate evaporated under reduced pressure affording the title compound which is used in the subsequent step without further purification.3. The volatiles are removed under reduced pressure and the residue is purified by flash chromatography on silica gel or by mass-directed reverse phase HPLC, affording the title compound; The intermediate is prepared according to General Procedure 1 using a solution of Intermediate A (10.0 g, 28.3 mmol) in DMF (110 mL), HATU (12.0 g, 31.6 mmol), tert-butyl 3,3- dimethylpiperazine-1-carboxylate (6.64, 31.0 mmol) and DIPEA (12.5 ml, 71.8 mmol) affording the title compound (15.38 g, quantitative yield) as a pale yellow solid, which is used directly in the next step. 1H NMR (400 MHz, DMSO-d6) 6 8.16 (dd, J = 11.0, 2.0 Hz, 1H), 8.07 - 7.97 (m, 1H), 7.82 (s, 1H), 7.76 - 7.64 (m, 1H), 7.51 (s, 1H), 3.85 (s, 2H), 3.57 - 3.38 (m, 4H), 1.52 (s, 1OH), 1.48 (s, 6H), 1.42 (s, 9H). ESI-MS m/z calc. 543.2300, found 546.10 (M+1) Retention time: 1.23 minutes using method J.

Reference： [1]Patent: WO2018/57588,2018,A1 .Location in patent: Paragraph 0154; 0221

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 259808-67-8 ]

Amides

[ 163765-44-4 ]

(R)-1-Boc-3-Methylpiperazine

Similarity: 0.96

[ 129779-30-2 ]

(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 180975-66-0 ]

tert-Butyl cis-2,6-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 639068-43-2 ]

tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 438049-91-3 ]

(3R,5R)-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Related Parent Nucleus of
[ 259808-67-8 ]

Aliphatic Heterocycles

[ 163765-44-4 ]

(R)-1-Boc-3-Methylpiperazine

Similarity: 0.96

[ 129779-30-2 ]

(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 180975-66-0 ]

tert-Butyl cis-2,6-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 639068-43-2 ]

tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 438049-91-3 ]

(3R,5R)-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Piperazines

[ 163765-44-4 ]

(R)-1-Boc-3-Methylpiperazine

Similarity: 0.96

[ 129779-30-2 ]

(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 180975-66-0 ]

tert-Butyl cis-2,6-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 639068-43-2 ]

tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

[ 438049-91-3 ]

(3R,5R)-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 259808-67-8 ] {[proInfo.proName]}

Quality Control of [ 259808-67-8 ]

Related Doc. of [ 259808-67-8 ]

Product Details of [ 259808-67-8 ]

Calculated chemistry of [ 259808-67-8 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 259808-67-8 ]

Application In Synthesis of [ 259808-67-8 ]

[ 259808-67-8 ] Synthesis Path-Upstream 1~3

[ 259808-67-8 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 259808-67-8 ]

Amides

Related Parent Nucleus of [ 259808-67-8 ]

Aliphatic Heterocycles

Piperazines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 259808-67-8 ]

Related Parent Nucleus of
[ 259808-67-8 ]